Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial by Laurent Arnaud, Marta Mosca, Anca Askanase, Vibeke Strand, Subhashis Banerjee, Shalabh Singhal, Coburn Hobar, Samantha Pomponi, Brandon Becker, Jiyoon Choi

Get full text